Stocks · News reference

TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est

Aug 3, 2026, 11:00 AMBenzinga Newsdesk

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 21, 2026, 2:18 PMAvi Kapoor
MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).
Read original at benzinga
ASST BKKT BTCUSD BTDR CLF
BenzingaAug 21, 2026, 1:47 PMBenzinga Newsdesk
Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG Therapeutics
Read original at benzinga
TGTX
BenzingaAug 7, 2026, 4:51 PMBenzinga Newsdesk
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $65 to $72.
Read original at benzinga
TGTX
BenzingaAug 3, 2026, 2:12 PMBenzinga Newsdesk
TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Read original at benzinga
TGTX